1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O

1	Cyclin	B
2	A	I
3	expression	O
4	is	O
5	repressed	O
6	in	O
7	quiescent	O
8	cells	O
9	by	O
10	E2F	B
11	acting	O
12	in	O
13	conjunction	O
14	with	O
15	its	O
16	pocket	O
17	protein	O
18	partners	O
19	Rb	B
20	,	O
21	p107	B
22	,	O
23	and	O
24	p130	B
25	;	O
26	however	O
27	,	O
28	v	B
29	-	I
30	Jun	I
31	overrides	O
32	this	O
33	control	O
34	,	O
35	causing	O
36	phosphorylated	O
37	Rb	B
38	and	O
39	proliferation	O
40	-	O
41	specific	O
42	E2F	B
43	-	O
44	p107	B
45	complexes	O
46	to	O
47	persist	O
48	after	O
49	mitogen	O
50	withdrawal	O
51	.	O

1	Animals	O
2	may	O
3	be	O
4	immunized	O
5	by	O
6	oral	O
7	vaccination	O
8	,	O
9	but	O
10	natural	O
11	mechanisms	O
12	that	O
13	also	O
14	can	O
15	terminate	O
16	outbreaks	O
17	are	O
18	discussed	O
19	.	O

1	(	O
2	3	O
3	).	O

1	Three	O
2	cDNAs	O
3	encoding	O
4	basic	B
5	leucine	I
6	zipper	I
7	(	I
8	bZIP	I
9	)-	I
10	type	I
11	ABRE	I
12	-	I
13	binding	I
14	proteins	I
15	were	O
16	isolated	O
17	by	O
18	using	O
19	the	O
20	yeast	O
21	one	O
22	-	O
23	hybrid	O
24	system	O
25	and	O
26	were	O
27	designated	O
28	AREB1	B
29	,	O
30	AREB2	B
31	,	O
32	and	O
33	AREB3	B
34	(	O
35	ABA	B
36	-	I
37	responsive	I
38	element	I
39	binding	I
40	protein	I
41	).	O

1	Hence	O
2	,	O
3	the	O
4	replacement	O
5	of	O
6	Phe	O
7	-	O
8	62	O
9	with	O
10	Ser	O
11	specifically	O
12	affects	O
13	a	O
14	determinant	O
15	on	O
16	the	O
17	lambda	B
18	I	I
19	light	I
20	chain	I
21	that	O
22	is	O
23	necessary	O
24	for	O
25	the	O
26	intracellular	O
27	transport	O
28	of	O
29	this	O
30	molecule	O
31	.	O

1	Double	O
2	-	O
3	blind	O
4	randomised	O
5	trial	O
6	of	O
7	intravenous	O
8	tissue	B
9	-	I
10	type	I
11	plasminogen	I
12	activator	I
13	versus	O
14	placebo	O
15	in	O
16	acute	O
17	myocardial	O
18	infarction	O
19	.	O

1	Sixteen	O
2	other	O
3	normal	O
4	subjects	O
5	with	O
6	2	O
7	g	O
8	of	O
9	Metyrapone	O
10	are	O
11	best	O
12	responses	O
13	.	O

1	Today	O
2	there	O
3	is	O
4	no	O
5	doubt	O
6	that	O
7	elevated	O
8	plasma	O
9	cholesterol	O
10	levels	O
11	should	O
12	be	O
13	lowered	O
14	first	O
15	by	O
16	dietary	O
17	modification	O
18	even	O
19	in	O
20	early	O
21	childhood	O
22	,	O
23	beginning	O
24	at	O
25	the	O
26	age	O
27	of	O
28	two	O
29	years	O
30	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	The	O
2	DNA	O
3	sequence	O
4	of	O
5	the	O
6	sulfate	B
7	activation	I
8	locus	I
9	from	O
10	Escherichia	O
11	coli	O
12	K	O
13	-	O
14	12	O
15	has	O
16	been	O
17	determined	O
18	.	O

1	As	O
2	the	O
3	rate	O
4	of	O
5	protein	O
6	synthesis	O
7	decreases	O
8	during	O
9	late	O
10	embryogenesis	O
11	,	O
12	levels	O
13	of	O
14	SEC	B
15	-	I
16	1	I
17	and	O
18	its	O
19	cognate	O
20	mRNA	O
21	decline	O
22	precipitously	O
23	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	clarify	O
7	the	O
8	location	O
9	of	O
10	a	O
11	transesophageal	O
12	echocardiographic	O
13	(	O
14	TEE	O
15	)	O
16	transducer	O
17	when	O
18	obtaining	O
19	the	O
20	short	O
21	-	O
22	axis	O
23	view	O
24	of	O
25	the	O
26	left	O
27	ventricle	O
28	(	O
29	S	O
30	-	O
31	LV	O
32	).	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serological	O
6	studies	O
7	,	O
8	the	O
9	highly	O
10	conserved	O
11	A	O
12	domain	O
13	of	O
14	HspA	B
15	was	O
16	found	O
17	to	O
18	be	O
19	the	O
20	immunodominant	O
21	domain	O
22	.	O

1	Interestingly	O
2	,	O
3	the	O
4	interaction	O
5	of	O
6	ZAP	B
7	-	I
8	70	I
9	with	O
10	the	O
11	motif	O
12	was	O
13	dependent	O
14	on	O
15	the	O
16	presence	O
17	of	O
18	both	O
19	ZAP	B
20	-	I
21	70	I
22	SH2	I
23	domains	I
24	and	O
25	both	O
26	of	O
27	the	O
28	tyrosine	O
29	residues	O
30	in	O
31	the	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	ZAP	B
37	-	I
38	70	I
39	interacts	O
40	with	O
41	two	O
42	phosphotyrosine	O
43	residues	O
44	and	O
45	that	O
46	the	O
47	binding	O
48	of	O
49	the	O
50	two	O
51	SH2	B
52	domains	I
53	is	O
54	cooperative	O
55	.	O

1	An	O
2	E	O
3	box	O
4	element	O
5	is	O
6	required	O
7	for	O
8	the	O
9	expression	O
10	of	O
11	the	O
12	ad4bp	B
13	gene	I
14	,	O
15	a	O
16	mammalian	B
17	homologue	I
18	of	I
19	ftz	I
20	-	I
21	f1	I
22	gene	I
23	,	O
24	which	O
25	is	O
26	essential	O
27	for	O
28	adrenal	O
29	and	O
30	gonadal	O
31	development	O
32	.	O

1	Effects	O
2	of	O
3	cortisone	O
4	,	O
5	starvation	O
6	,	O
7	and	O
8	rickets	O
9	on	O
10	oxidative	O
11	enzyme	O
12	activities	O
13	of	O
14	epiphyseal	O
15	cartilage	O
16	from	O
17	rats	O
18	.	O

1	Molecular	O
2	and	O
3	functional	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	of	O
9	ETS2	B
10	,	O
11	the	O
12	human	O
13	c	B
14	-	I
15	ets	I
16	-	I
17	2	I
18	gene	O
19	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Raf	B
5	-	I
6	1	I
7	kinase	I
8	by	O
9	cyclic	O
10	AMP	O
11	agonists	O
12	causes	O
13	apoptosis	O
14	of	O
15	v	B
16	-	I
17	abl	I
18	-	O
19	transformed	O
20	cells	O
21	.	O

1	The	O
2	MMA	B
3	,	I
4	DMA	I
5	,	I
6	and	I
7	TMA	I
8	methyltransferases	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	B
26	and	I
27	TMA	I
28	methyltransferases	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	Specifically	O
2	,	O
3	by	O
4	the	O
5	type	O
6	of	O
7	adjuvant	O
8	therapy	O
9	,	O
10	the	O
11	median	O
12	disease	O
13	-	O
14	free	O
15	interval	O
16	and	O
17	survival	O
18	from	O
19	stage	O
20	IVA	O
21	for	O
22	23	O
23	patients	O
24	receiving	O
25	Corynebacterium	O
26	parvum	O
27	were	O
28	6	O
29	.	O
30	9	O
31	and	O
32	19	O
33	months	O
34	;	O
35	for	O
36	39	O
37	patients	O
38	receiving	O
39	BCG	O
40	,	O
41	eight	O
42	months	O
43	and	O
44	26	O
45	months	O
46	;	O
47	for	O
48	24	O
49	patients	O
50	receiving	O
51	BCG	O
52	+	O
53	DTIC	O
54	,	O
55	eight	O
56	and	O
57	17	O
58	.	O
59	4	O
60	months	O
61	;	O
62	and	O
63	for	O
64	all	O
65	51	O
66	DTIC	O
67	treated	O
68	patients	O
69	6	O
70	.	O
71	3	O
72	and	O
73	17	O
74	.	O
75	8	O
76	months	O
77	,	O
78	respectively	O
79	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	to	O
8	occur	O
9	66	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	initiating	O
15	Met	O
16	.	O

1	(	O
2	2	O
3	)	O
4	Erythroid	O
5	32D	O
6	Epo1	B
7	cells	O
8	showed	O
9	a	O
10	lower	O
11	level	O
12	of	O
13	bulk	O
14	PKC	B
15	catalytic	O
16	activity	O
17	,	O
18	lacked	O
19	the	O
20	expression	O
21	of	O
22	epsilon	B
23	and	I
24	eta	I
25	PKC	I
26	isoforms	I
27	,	O
28	and	O
29	showed	O
30	a	O
31	weak	O
32	or	O
33	absent	O
34	upregulation	O
35	of	O
36	the	O
37	remaining	O
38	isoforms	O
39	,	O
40	except	O
41	betaI	B
42	,	O
43	upon	O
44	readdition	O
45	of	O
46	Epo	B
47	to	O
48	growth	O
49	factor	O
50	-	O
51	starved	O
52	cells	O
53	.	O

1	Thus	O
2	,	O
3	in	O
4	stress	O
5	-	O
6	induced	O
7	arrhythmic	O
8	disease	O
9	as	O
10	well	O
11	as	O
12	in	O
13	ischemic	O
14	heart	O
15	disease	O
16	,	O
17	the	O
18	main	O
19	pathogenetic	O
20	links	O
21	are	O
22	outside	O
23	the	O
24	heart	O
25	,	O
26	but	O
27	they	O
28	differ	O
29	from	O
30	those	O
31	observed	O
32	in	O
33	ischemia	O
34	.	O

1	e	O
2	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	The	O
2	murine	B
3	Mov	I
4	-	I
5	34	I
6	gene	I
7	:	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	and	O
13	genomic	O
14	organization	O
15	.	O

1	Salzburg	O
2	,	O
3	9	O
4	-	O
5	12	O
6	September	O
7	1987	O
8	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	Specialized	O
2	actin	B
3	tails	O
4	that	O
5	propel	O
6	IEV	O
7	particles	O
8	to	O
9	the	O
10	periphery	O
11	and	O
12	virus	O
13	-	O
14	tipped	O
15	microvilli	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	vA33delta	O
34	.	O

1	These	O
2	repressor	O
3	sites	O
4	are	O
5	pyrimidine	O
6	rich	O
7	and	O
8	bind	O
9	avidly	O
10	to	O
11	the	O
12	polypyrimidine	B
13	tract	I
14	binding	I
15	protein	I
16	(	O
17	PTB	B
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	O
26	UV	O
27	crosslinking	O
28	/	O
29	competition	O
30	assays	O
31	.	O

1	Members	O
2	of	O
3	the	O
4	Ras	B
5	subfamily	I
6	of	O
7	small	B
8	GTP	I
9	-	I
10	binding	I
11	proteins	I
12	have	O
13	been	O
14	shown	O
15	to	O
16	be	O
17	promiscuous	O
18	towards	O
19	a	O
20	variety	O
21	of	O
22	putative	O
23	effector	O
24	molecules	O
25	such	O
26	as	O
27	the	O
28	protein	B
29	kinase	I
30	c	I
31	-	I
32	Raf	I
33	and	O
34	the	O
35	Ral	B
36	-	I
37	specific	I
38	guanine	I
39	nucleotide	I
40	exchange	I
41	factor	I
42	(	O
43	Ral	B
44	-	I
45	GEF	I
46	).	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	assess	O
7	and	O
8	compare	O
9	the	O
10	ability	O
11	of	O
12	three	O
13	different	O
14	forms	O
15	of	O
16	DSG	O
17	to	O
18	block	O
19	EIB	O
20	.	O

1	Whole	O
2	-	O
3	mount	O
4	in	O
5	situ	O
6	hybridization	O
7	to	O
8	early	O
9	mouse	O
10	embryos	O
11	of	O
12	9	O
13	.	O
14	5	O
15	-	O
16	10	O
17	.	O
18	5	O
19	days	O
20	indicated	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	Arp1	B
26	expression	O
27	spatially	O
28	overlapping	O
29	with	O
30	the	O
31	expression	O
32	of	O
33	All1	B
34	.	O

1	Transcription	O
2	start	O
3	sites	O
4	of	O
5	the	O
6	plastid	O
7	ACCase	B
8	genes	I
9	were	O
10	estimated	O
11	from	O
12	the	O
13	longest	O
14	cDNA	O
15	clones	O
16	obtained	O
17	by	O
18	5	O
19	'-	O
20	RACE	O
21	(	O
22	rapid	O
23	amplification	O
24	of	O
25	cDNA	O
26	ends	O
27	).	O

1	By	O
2	using	O
3	lambda	O
4	gt11	O
5	expression	O
6	cloning	O
7	with	O
8	oligonucleotides	O
9	corresponding	O
10	to	O
11	the	O
12	human	O
13	immunodeficiency	O
14	virus	O
15	1	O
16	TATA	O
17	element	O
18	,	O
19	we	O
20	report	O
21	the	O
22	identification	O
23	of	O
24	a	O
25	cellular	O
26	protein	O
27	with	O
28	a	O
29	calculated	O
30	molecular	O
31	mass	O
32	of	O
33	123	O
34	kDa	O
35	that	O
36	we	O
37	designate	O
38	TATA	B
39	element	I
40	modulatory	I
41	factor	I
42	(	O
43	TMF	B
44	).	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O

1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	B
16	IgE	I
17	antibodies	I

1	Grade	O
2	3	O
3	mucositis	O
4	was	O
5	reported	O
6	in	O
7	1	O
8	patient	O
9	.	O

1	An	O
2	open	O
3	-	O
4	label	O
5	,	O
6	placebo	O
7	-	O
8	controlled	O
9	,	O
10	randomized	O
11	,	O
12	two	O
13	-	O
14	way	O
15	crossover	O
16	study	O
17	was	O
18	performed	O
19	in	O
20	12	O
21	healthy	O
22	volunteers	O
23	(	O
24	between	O
25	20	O
26	and	O
27	44	O
28	years	O
29	of	O
30	age	O
31	)	O
32	to	O
33	assess	O
34	the	O
35	effect	O
36	of	O
37	orlistat	O
38	,	O
39	a	O
40	gastrointestinal	B
41	lipase	I
42	inhibitor	O
43	that	O
44	reduces	O
45	dietary	O
46	fat	O
47	absorption	O
48	and	O
49	is	O
50	being	O
51	developed	O
52	for	O
53	weight	O
54	control	O
55	in	O
56	obesity	O
57	,	O
58	on	O
59	the	O
60	absorption	O
61	of	O
62	vitamins	O
63	A	O
64	and	O
65	E	O
66	.	O

1	DtxR	B
2	is	O
3	an	O
4	iron	O
5	-	O
6	dependent	O
7	sequence	O
8	-	O
9	specific	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	the	O
18	tox	B
19	operator	I
20	,	O
21	an	O
22	inverted	O
23	-	O
24	repeat	O
25	nucleotide	O
26	sequence	O
27	located	O
28	upstream	O
29	from	O
30	the	O
31	diphtheria	B
32	toxin	I
33	gene	I
34	.	O

1	Cyclin	B
2	D1	I
3	could	O
4	not	O
5	be	O
6	displaced	O
7	from	O
8	cdk4	B
9	in	O
10	the	O
11	resistant	O
12	184A1L5R	O
13	cell	O
14	lysates	O
15	.	O

1	A	O
2	.	O

1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	nuclear	I
6	protein	I
7	2	I
8	(	O
9	EBNA2	B
10	)	O
11	binds	O
12	to	O
13	a	O
14	component	O
15	of	O
16	the	O
17	human	O
18	SNF	B
19	-	O
20	SWI	B
21	complex	O
22	,	O
23	hSNF5	B
24	/	O
25	Ini1	B
26	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	isolated	O
6	genomic	O
7	clone	O
8	revealed	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	of	O
15	this	O
16	orphan	O
17	receptor	O
18	is	O
19	most	O
20	homologous	O
21	to	O
22	the	O
23	human	B
24	TR2	I
25	receptor	I
26	.	O

1	Similarly	O
2	,	O
3	PCDFs	O
4	/	O
5	PCDDs	O
6	ratio	O
7	in	O
8	ESP	O
9	ash	O
10	was	O
11	lower	O
12	than	O
13	that	O
14	in	O
15	boiler	O
16	ash	O
17	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	O
12	proteins	O
13	and	O
14	RNA	B
15	polymerase	I
16	II	I
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O

1	Gel	O
2	shift	O
3	analysis	O
4	indicates	O
5	that	O
6	the	O
7	full	B
8	-	I
9	length	I
10	ERM	I
11	protein	I
12	is	O
13	able	O
14	to	O
15	bind	O
16	specifically	O
17	to	O
18	an	O
19	oligonucleotide	O
20	containing	O
21	the	O
22	consensus	O
23	nucleotide	O
24	core	O
25	sequence	O
26	GGAA	O
27	recognized	O
28	by	O
29	the	O
30	Ets	B
31	proteins	O
32	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	analyze	O
9	the	O
10	common	O
11	cause	O
12	of	O
13	asthenopia	O
14	,	O
15	mixed	O
16	astigmatism	O
17	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	a	O
6	)	O
7	the	O
8	likelihood	O
9	of	O
10	detecting	O
11	carcinoma	O
12	or	O
13	atypical	O
14	hyperplasia	O
15	exclusively	O
16	in	O
17	the	O
18	adipose	O
19	tissue	O
20	component	O
21	of	O
22	grossly	O
23	benign	O
24	breast	O
25	biopsies	O
26	is	O
27	extremely	O
28	low	O
29	,	O
30	and	O
31	(	O
32	b	O
33	)	O
34	a	O
35	possible	O
36	cost	O
37	-	O
38	effective	O
39	method	O
40	of	O
41	sampling	O
42	grossly	O
43	benign	O
44	breast	O
45	biopsies	O
46	consists	O
47	of	O
48	initially	O
49	submitting	O
50	a	O
51	maximum	O
52	of	O
53	10	O
54	blocks	O
55	of	O
56	fibrous	O
57	parenchyma	O
58	for	O
59	each	O
60	case	O
61	,	O
62	then	O
63	examining	O
64	the	O
65	remaining	O
66	tissue	O
67	histologically	O
68	only	O
69	if	O
70	carcinoma	O
71	or	O
72	atypical	O
73	hyperplasia	O
74	is	O
75	found	O
76	among	O
77	these	O
78	blocks	O
79	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	B
12	and	O
13	hepatic	B
14	leukemia	I
15	factor	I
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	O
28	DBP	B
29	fusion	O
30	proteins	O
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	Renin	B
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	B
21	renin	I
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O

1	We	O
2	conclude	O
3	that	O
4	class	O
5	I	O
6	cytologic	O
7	smears	O
8	with	O
9	moderate	O
10	to	O
11	severe	O
12	inflammation	O
13	may	O
14	be	O
15	associated	O
16	with	O
17	findings	O
18	of	O
19	condylomata	O
20	and	O
21	cervical	O
22	dysplasia	O
23	.	O

1	In	O
2	summary	O
3	,	O
4	p56	B
5	(	O
6	lck	B
7	)	O
8	activity	O
9	stimulates	O
10	G1	O
11	/	O
12	S	O
13	transition	O
14	in	O
15	immature	O
16	thymoblasts	O
17	and	O
18	maintains	O
19	cell	O
20	viability	O
21	via	O
22	transduction	O
23	of	O
24	constitutive	O
25	activation	O
26	signals	O
27	downstream	O
28	to	O
29	components	O
30	of	O
31	the	O
32	Ras	B
33	/	O
34	Raf	B
35	/	O
36	MAPK	B
37	pathway	O
38	.	O

1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O

1	Atherosclerosis	O

1	Detection	O
2	of	O
3	exercise	O
4	-	O
5	induced	O
6	asynergy	O
7	by	O
8	M	O
9	-	O
10	mode	O
11	echocardiography	O
12	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	100	O
7	-	O
8	kDa	O
9	mammalian	O
10	protein	O
11	,	O
12	which	O
13	was	O
14	recognized	O
15	by	O
16	an	O
17	anti	O
18	-	O
19	peptide	O
20	antibody	O
21	against	O
22	an	O
23	epitope	O
24	-	O
25	containing	O
26	nuclear	O
27	localization	O
28	signal	O
29	of	O
30	NF	B
31	-	I
32	kappaB	I
33	p65	I
34	subunit	I
35	.	O

1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	pre	B
6	-	I
7	C	I
8	and	O
9	pregenomic	O
10	promoters	O
11	of	O
12	human	O
13	hepatitis	O
14	B	O
15	virus	O
16	by	O
17	members	O
18	of	O
19	the	O
20	nuclear	B
21	receptor	I
22	superfamily	I
23	.	O

1	Estimated	O
2	daily	O
3	intakes	O
4	(	O
5	EDIs	O
6	)	O
7	per	O
8	person	O
9	were	O
10	0	O
11	.	O
12	56	O
13	microgram	O
14	for	O
15	total	O
16	HCH	O
17	,	O
18	0	O
19	.	O
20	20	O
21	microgram	O
22	for	O
23	gamma	O
24	-	O
25	HCH	O
26	,	O
27	0	O
28	.	O
29	09	O
30	microgram	O
31	for	O
32	dieldrin	O
33	,	O
34	1	O
35	.	O
36	42	O
37	micrograms	O
38	for	O
39	total	O
40	DDT	O
41	,	O
42	and	O
43	0	O
44	.	O
45	15	O
46	microgram	O
47	for	O
48	HCB	O
49	.	O

1	The	O
2	unfolded	O
3	protein	O
4	response	O
5	regulates	O
6	multiple	O
7	aspects	O
8	of	O
9	secretory	O
10	and	O
11	membrane	O
12	protein	O
13	biogenesis	O
14	and	O
15	endoplasmic	O
16	reticulum	O
17	quality	O
18	control	O
19	.	O

1	Differences	O
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O

1	We	O
2	report	O
3	a	O
4	prevalence	O
5	study	O
6	of	O
7	the	O
8	best	O
9	visual	O
10	acuity	O
11	in	O
12	the	O
13	affected	O
14	eye	O
15	of	O
16	100	O
17	selected	O
18	patients	O
19	with	O
20	herpetic	O
21	keratitis	O
22	seen	O
23	during	O
24	a	O
25	two	O
26	-	O
27	year	O
28	period	O
29	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	O
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	I
29	element	I
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	I
37	transcriptional	I
38	element	I

1	We	O
2	have	O
3	investigated	O
4	the	O
5	contribution	O
6	of	O
7	specific	O
8	TATA	B
9	-	I
10	binding	I
11	protein	I
12	(	O
13	TBP	B
14	)-	O
15	TATA	O
16	interactions	O
17	to	O
18	the	O
19	promoter	O
20	activity	O
21	of	O
22	a	O
23	constitutively	O
24	expressed	O
25	silkworm	B
26	tRNA	I
27	(	I
28	C	I
29	)(	I
30	Ala	I
31	)	I
32	gene	I
33	and	O
34	have	O
35	also	O
36	asked	O
37	whether	O
38	the	O
39	lack	O
40	of	O
41	similar	O
42	interactions	O
43	accounts	O
44	for	O
45	the	O
46	low	O
47	promoter	O
48	activity	O
49	of	O
50	a	O
51	silk	B
52	gland	I
53	-	I
54	specific	I
55	tRNA	I
56	(	I
57	SG	I
58	)(	I
59	Ala	I
60	)	I
61	gene	I
62	.	O

1	Significantly	O
2	,	O
3	two	O
4	proximal	O
5	GATA	B
6	-	I
7	1	I
8	-	I
9	binding	I
10	sites	I
11	(-	O
12	118	O
13	/-	O
14	113	O
15	and	O
16	-	O
17	98	O
18	/-	O
19	93	O
20	)	O
21	and	O
22	a	O
23	region	O
24	located	O
25	within	O
26	-	O
27	518	O
28	to	O
29	-	O
30	315bp	O
31	of	O
32	the	O
33	mouse	B
34	ALAS2	I
35	promoter	I
36	were	O
37	essential	O
38	for	O
39	transcriptional	O
40	activation	O
41	during	O
42	chemically	O
43	induced	O
44	differentiation	O
45	of	O
46	MEL	O
47	cells	O
48	,	O
49	implying	O
50	their	O
51	importance	O
52	in	O
53	conferring	O
54	erythroid	O
55	specificity	O
56	to	O
57	the	O
58	ALAS2	B
59	transcriptional	O
60	activation	O
61	.	O

1	In	O
2	a	O
3	previous	O
4	study	O
5	(	O
6	Brandl	O
7	,	O
8	C	O
9	.	O

1	During	O
2	a	O
3	28	O
4	-	O
5	week	O
6	promotion	O
7	bioassay	O
8	,	O
9	groups	O
10	of	O
11	30	O
12	male	O
13	CD	O
14	-	O
15	1	O
16	mice	O
17	were	O
18	treated	O
19	once	O
20	with	O
21	50	O
22	microliter	O
23	of	O
24	either	O
25	DMBA	O
26	(	O
27	1	O
28	.	O
29	0	O
30	mg	O
31	/	O
32	ml	O
33	)	O
34	or	O
35	acetone	O
36	,	O
37	rested	O
38	for	O
39	2	O
40	weeks	O
41	,	O
42	and	O
43	then	O
44	treated	O
45	twice	O
46	per	O
47	week	O
48	with	O
49	test	O
50	material	O
51	for	O
52	the	O
53	remaining	O
54	25	O
55	weeks	O
56	.	O

1	STP1	B
2	is	O
3	an	O
4	unessential	O
5	yeast	O
6	gene	O
7	involved	O
8	in	O
9	the	O
10	removal	O
11	of	O
12	intervening	O
13	sequences	O
14	from	O
15	some	O
16	,	O
17	but	O
18	not	O
19	all	O
20	,	O
21	families	O
22	of	O
23	intervening	O
24	sequence	O
25	-	O
26	containing	O
27	pre	O
28	-	O
29	tRNAs	O
30	.	O

1	Analysis	O
2	in	O
3	3	O
4	groups	O
5	of	O
6	patients	O
7	suffering	O
8	from	O
9	simple	O
10	acute	O
11	and	O
12	pernicious	O
13	malarial	O
14	flare	O
15	-	O
16	ups	O

1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	vasodilator	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	vasodilation	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	preserved	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O

1	Activities	O
2	of	O
3	hepatic	O
4	cytochrome	B
5	P	I
6	-	I
7	450	I
8	-	O
9	dependent	O
10	metabolizing	O
11	enzymes	O
12	such	O
13	as	O
14	aminopyrine	B
15	-	I
16	and	I
17	TMO	I
18	N	I
19	-	I
20	demethylase	I
21	and	O
22	aniline	B
23	hydroxylase	I
24	activity	O
25	were	O
26	decreased	O
27	by	O
28	pretreatment	O
29	of	O
30	rats	O
31	with	O
32	cimetidine	O
33	,	O
34	whereas	O
35	in	O
36	the	O
37	rats	O
38	pretreated	O
39	with	O
40	ranitidine	O
41	,	O
42	these	O
43	enzyme	O
44	activities	O
45	were	O
46	not	O
47	changed	O
48	.	O

1	During	O
2	latency	O
3	,	O
4	more	O
5	than	O
6	1	O
7	%	O
8	of	O
9	neurons	O
10	in	O
11	ganglia	O
12	that	O
13	innervate	O
14	the	O
15	footpad	O
16	expressed	O
17	beta	B
18	-	I
19	galactosidase	I
20	,	O
21	with	O
22	the	O
23	number	O
24	of	O
25	positive	O
26	cells	O
27	remaining	O
28	constant	O
29	for	O
30	at	O
31	least	O
32	5	O
33	months	O
34	.	O

1	Clinical	O
2	findings	O
3	were	O
4	:	O
5	height	O
6	183	O
7	cm	O
8	,	O
9	weight	O
10	62	O
11	kg	O
12	,	O
13	increased	O
14	length	O
15	of	O
16	lower	O
17	limbs	O
18	,	O
19	P2	O
20	-	O
21	A2	O
22	pilosity	O
23	and	O
24	micropenis	O
25	.	O

1	It	O
2	was	O
3	subsequently	O
4	shown	O
5	that	O
6	Tip60	B
7	had	O
8	histone	B
9	acetyltransferase	I
10	(	O
11	HAT	B
12	)	O
13	activity	O
14	.	O

1	ERK	B
2	MAP	I
3	kinase	I
4	links	O
5	cytokine	O
6	signals	O
7	to	O
8	activation	O
9	of	O
10	latent	O
11	HIV	O
12	-	O
13	1	O
14	infection	O
15	by	O
16	stimulating	O
17	a	O
18	cooperative	O
19	interaction	O
20	of	O
21	AP	B
22	-	I
23	1	I
24	and	O
25	NF	B
26	-	I
27	kappaB	I
28	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	view	O
6	that	O
7	clonidine	O
8	and	O
9	6	O
10	-	O
11	OHDA	O
12	,	O
13	but	O
14	not	O
15	alpha	O
16	-	O
17	MD	O
18	,	O
19	have	O
20	central	O
21	pressor	O
22	actions	O
23	in	O
24	the	O
25	rat	O
26	that	O
27	oppose	O
28	their	O
29	antihypertensive	O
30	action	O
31	.	O

1	Mutation	O
2	of	O
3	KRKR	O
4	to	O
5	NGER	O
6	retains	O
7	MO15	B
8	in	O
9	the	O
10	cytoplasmic	O
11	compartment	O
12	,	O
13	whilst	O
14	the	O
15	wild	O
16	-	O
17	type	O
18	protein	O
19	is	O
20	detected	O
21	exclusively	O
22	in	O
23	the	O
24	nucleus	O
25	.	O

1	CREB	B
2	was	O
3	identified	O
4	as	O
5	one	O
6	of	O
7	the	O
8	protein	O
9	components	O
10	in	O
11	several	O
12	of	O
13	the	O
14	gel	O
15	shift	O
16	complexes	O
17	formed	O
18	with	O
19	the	O
20	variant	O
21	CRE	O
22	.	O

1	We	O
2	also	O
3	provide	O
4	evidence	O
5	that	O
6	neither	O
7	the	O
8	lambda	B
9	O	I
10	and	O
11	P	B
12	initiators	I
13	nor	O
14	the	O
15	E	B
16	.	I
17	coli	I
18	DnaJ	I
19	and	O
20	DnaK	B
21	heat	O
22	shock	O
23	proteins	O
24	play	O
25	a	O
26	direct	O
27	role	O
28	in	O
29	the	O
30	propagation	O
31	of	O
32	lambda	O
33	replication	O
34	forks	O
35	in	O
36	vitro	O
37	.	O

1	The	O
2	subepicardial	O
3	lymphatic	O
4	capillaries	O
5	were	O
6	ramified	O
7	and	O
8	anastomosed	O
9	with	O
10	each	O
11	other	O
12	to	O
13	form	O
14	a	O
15	relatively	O
16	dense	O
17	network	O
18	which	O
19	extended	O
20	over	O
21	the	O
22	entire	O
23	surface	O
24	of	O
25	both	O
26	ventricles	O
27	.	O

1	In	O
2	the	O
3	icosahaedral	O
4	MVMi	O
5	capsid	O
6	,	O
7	this	O
8	sequence	O
9	forms	O
10	the	O
11	carboxy	O
12	end	O
13	of	O
14	the	O
15	amphipathic	O
16	beta	O
17	-	O
18	strand	O
19	I	O
20	(	O
21	betaI	O
22	),	O
23	and	O
24	all	O
25	its	O
26	basic	O
27	residues	O
28	are	O
29	contiguously	O
30	positioned	O
31	at	O
32	the	O
33	face	O
34	that	O
35	in	O
36	the	O
37	unassembled	O
38	subunit	O
39	would	O
40	be	O
41	exposed	O
42	to	O
43	solvent	O
44	.	O

1	A	O
2	736	O
3	-	O
4	bp	O
5	sequence	O
6	of	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	adjacent	O
13	to	O
14	the	O
15	cap	O
16	site	O
17	of	O
18	the	O
19	human	B
20	AFP	I
21	gene	I
22	shows	O
23	a	O
24	61	O
25	%	O
26	similarity	O
27	with	O
28	the	O
29	corresponding	O
30	region	O
31	of	O
32	the	O
33	mouse	B
34	AFP	I
35	gene	I
36	.	O

1	Materials	O
2	science	O
3	studies	O
4	on	O
5	the	O
6	soldering	O
7	of	O
8	different	O
9	orthodontic	O
10	wires	O

1	RESULTS	O
2	:	O
3	The	O
4	bilinear	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	fit	O
11	to	O
12	the	O
13	acuity	O
14	outcome	O
15	data	O
16	.	O

1	Approximately	O
2	65	O
3	%	O
4	of	O
5	the	O
6	total	O
7	cAMP	B
8	-	I
9	dependent	I
10	phosphotransferase	I
11	activity	O
12	is	O
13	recovered	O
14	in	O
15	particulate	O
16	fractions	O
17	of	O
18	homogenates	O
19	prepared	O
20	from	O
21	asynchronous	O
22	populations	O
23	of	O
24	C	O
25	.	O
26	elegans	O
27	.	O

1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	one	O
6	healthy	O
7	eyes	O
8	,	O
9	169	O
10	ocular	O
11	hypertensive	O
12	eyes	O
13	with	O
14	normal	O
15	visual	O
16	fields	O
17	,	O
18	and	O
19	132	O
20	glaucomatous	O
21	eyes	O
22	with	O
23	early	O
24	visual	O
25	field	O
26	defects	O
27	were	O
28	evaluated	O
29	with	O
30	qualitative	O
31	and	O
32	quantitative	O
33	measures	O
34	of	O
35	structural	O
36	damage	O
37	to	O
38	the	O
39	optic	O
40	nerve	O
41	and	O
42	nerve	O
43	fiber	O
44	layer	O
45	.	O

1	Enhancers	O
2	containing	O
3	disrupted	O
4	Ets	B
5	-	I
6	1	I
7	binding	I
8	sites	I
9	were	O
10	tested	O
11	in	O
12	transient	O
13	expression	O
14	assays	O
15	in	O
16	the	O
17	murine	O
18	T	O
19	-	O
20	cell	O
21	line	O
22	EL4	O
23	.	O
24	E1	O
25	;	O
26	alterations	O
27	in	O
28	the	O
29	LVb	O
30	element	O
31	affected	O
32	constitutive	O
33	enhancer	O
34	activity	O
35	,	O
36	while	O
37	mutation	O
38	of	O
39	either	O
40	the	O
41	LVb	O
42	or	O
43	LVc	O
44	element	O
45	disrupted	O
46	phorbol	O
47	ester	O
48	-	O
49	induced	O
50	enhancer	O
51	activity	O
52	.	O

1	The	O
2	indoor	O
3	radon	O
4	concentration	O
5	in	O
6	the	O
7	summer	O
8	(	O
9	1990	O
10	)	O
11	period	O
12	ranged	O
13	between	O
14	8	O
15	and	O
16	81	O
17	Bq	O
18	m	O
19	-	O
20	3	O
21	,	O
22	while	O
23	in	O
24	the	O
25	winter	O
26	(	O
27	1989	O
28	-	O
29	1990	O
30	)	O
31	it	O
32	ranged	O
33	between	O
34	20	O
35	and	O
36	143	O
37	Bq	O
38	m	O
39	-	O
40	3	O
41	for	O
42	the	O
43	first	O
44	year	O
45	of	O
46	measurements	O
47	or	O
48	between	O
49	8	O
50	and	O
51	92	O
52	Bq	O
53	m	O
54	-	O
55	3	O
56	in	O
57	the	O
58	summer	O
59	(	O
60	1991	O
61	)	O
62	period	O
63	and	O
64	between	O
65	12	O
66	and	O
67	119	O
68	Bq	O
69	m	O
70	-	O
71	3	O
72	in	O
73	the	O
74	winter	O
75	(	O
76	1990	O
77	-	O
78	1991	O
79	)	O
80	for	O
81	the	O
82	second	O
83	year	O
84	of	O
85	measurements	O
86	.	O

1	Four	O
2	patients	O
3	(	O
4	group	O
5	1	O
6	)	O
7	had	O
8	type	O
9	I	O
10	basement	O
11	membrane	O
12	nephropathy	O
13	,	O
14	characterized	O
15	by	O
16	marked	O
17	thickening	O
18	and	O
19	lamellation	O
20	of	O
21	the	O
22	basement	O
23	membrane	O
24	in	O
25	a	O
26	pattern	O
27	resembling	O
28	that	O
29	of	O
30	Alport	O
31	'	O
32	s	O
33	syndrome	O
34	.	O

1	Relationship	O
2	of	O
3	CDK	B
4	-	I
5	activating	I
6	kinase	I
7	and	O
8	RNA	B
9	polymerase	I
10	II	I
11	CTD	O
12	kinase	O
13	TFIIH	B
14	/	O
15	TFIIK	B
16	.	O

1	Kidney	O
2	weight	O
3	and	O
4	kidney	O
5	-	O
6	to	O
7	-	O
8	body	O
9	weight	O
10	ratio	O
11	were	O
12	significantly	O
13	elevated	O
14	at	O
15	the	O
16	highest	O
17	dose	O
18	level	O
19	after	O
20	10	O
21	weeks	O
22	and	O
23	at	O
24	the	O
25	two	O
26	higher	O
27	dose	O
28	levels	O
29	after	O
30	15	O
31	weeks	O
32	of	O
33	exposure	O
34	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	suggest	O
7	that	O
8	the	O
9	Mif2	B
10	protein	I
11	interacts	O
12	with	O
13	Cep1p	B
14	at	O
15	the	O
16	centromere	O
17	and	O
18	that	O
19	the	O
20	yeast	O
21	centromere	O
22	indeed	O
23	exists	O
24	as	O
25	a	O
26	higher	O
27	order	O
28	protein	O
29	-	O
30	DNA	O
31	complex	O
32	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	MEMA	B
7	protein	I
8	is	O
9	identical	O
10	with	O
11	a	O
12	160	B
13	kDa	I
14	nuclear	I
15	'	I
16	domain	I
17	rich	I
18	in	I
19	serines	I
20	'	I
21	(	I
22	DRS	I
23	)	I
24	protein	I
25	occurring	O
26	free	O
27	in	O
28	the	O
29	nucleoplasm	O
30	and	O
31	in	O
32	U2	B
33	-	I
34	ribonucleoprotein	I
35	structures	I
36	.	O

1	During	O
2	the	O
3	aftermath	O
4	of	O
5	excitation	O
6	of	O
7	the	O
8	skin	O
9	sympathetic	O
10	nerve	O
11	by	O
12	mental	O
13	arithmetics	O
14	,	O
15	3	O
16	/	O
17	12	O
18	A	O
19	delta	O
20	units	O
21	were	O
22	turned	O
23	to	O
24	the	O
25	active	O
26	state	O
27	with	O
28	decreased	O
29	mechanical	O
30	threshold	O
31	.	O

1	Logistic	O
2	regression	O
3	analysis	O
4	revealed	O
5	that	O
6	physicians	O
7	were	O
8	3	O
9	.	O
10	6	O
11	times	O
12	more	O
13	likely	O
14	to	O
15	detect	O
16	thin	O
17	lesions	O
18	(</=	O
19	0	O
20	.	O
21	75	O
22	mm	O
23	)	O
24	compared	O
25	with	O
26	nonphysician	O
27	detectors	O
28	(	O
29	95	O
30	%	O
31	confidence	O
32	interval	O
33	[	O
34	95	O
35	%	O
36	CI	O
37	],	O
38	2	O
39	.	O
40	1	O
41	,	O
42	6	O
43	.	O
44	5	O
45	;	O
46	P	O
47	=	O
48	0	O
49	.	O
50	0001	O
51	).	O

1	2	O
2	:	O
3	121	O
4	-	O
5	133	O
6	,	O
7	1988	O
8	).	O

1	Upon	O
2	induction	O
3	of	O
4	SOS	O
5	,	O
6	viability	O
7	increased	O
8	2	O
9	-	O
10	6	O
11	-	O
12	fold	O
13	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	the	O
7	gene	O
8	encoding	O
9	the	O
10	human	B
11	U1	I
12	-	I
13	70K	I
14	snRNP	I
15	protein	I
16	.	O

1	The	O
2	effects	O
3	of	O
4	contrast	O
5	media	O
6	on	O
7	coagulation	B
8	factor	I
9	XII	I
10	.	O

1	Ecthyma	O
2	,	O
3	a	O
4	known	O
5	disease	O
6	,	O
7	of	O
8	which	O
9	little	O
10	is	O
11	known	O

1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	The	O
2	statistical	O
3	significance	O
4	of	O
5	the	O
6	prognosis	O
7	factors	O
8	was	O
9	studied	O
10	by	O
11	uni	O
12	-	O
13	and	O
14	multivariative	O
15	methods	O
16	,	O
17	according	O
18	to	O
19	the	O
20	model	O
21	of	O
22	Cox	O
23	,	O
24	with	O
25	the	O
26	help	O
27	of	O
28	an	O
29	IMB	O
30	computer	O
31	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Semen	O
6	analyses	O
7	were	O
8	performed	O
9	on	O
10	58	O
11	patients	O
12	with	O
13	stages	O
14	I	O
15	-	O
16	III	O
17	HD	O
18	before	O
19	,	O
20	during	O
21	,	O
22	and	O
23	after	O
24	chemotherapy	O
25	and	O
26	after	O
27	the	O
28	sperm	O
29	count	O
30	recovered	O
31	from	O
32	the	O
33	effects	O
34	of	O
35	abdominal	O
36	radiotherapy	O
37	that	O
38	was	O
39	given	O
40	after	O
41	chemotherapy	O
42	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	expression	O
7	of	O
8	a	O
9	tumour	O
10	derived	O
11	brk	B
12	cDNA	I
13	in	O
14	mouse	O
15	embryonic	O
16	fibroblasts	O
17	and	O
18	human	O
19	mammary	O
20	epithelial	O
21	cells	O
22	supports	O
23	anchorage	O
24	independent	O
25	growth	O
26	,	O
27	and	O
28	in	O
29	the	O
30	latter	O
31	potentiates	O
32	the	O
33	mitogenic	O
34	response	O
35	to	O
36	epidermal	B
37	growth	I
38	factor	I
39	.	O

1	Bone	O
2	marrow	O
3	abnormalities	O
4	in	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O
9	are	O
10	reviewed	O
11	and	O
12	the	O
13	current	O
14	understanding	O
15	of	O
16	the	O
17	pathological	O
18	mechanisms	O
19	leading	O
20	to	O
21	aplastic	O
22	anemia	O
23	is	O
24	discussed	O
25	.	O

1	The	O
2	calculated	O
3	values	O
4	of	O
5	lambda	O
6	tb	O
7	at	O
8	37	O
9	degrees	O
10	C	O
11	and	O
12	50	O
13	per	O
14	cent	O
15	haematocrit	O
16	were	O
17	0	O
18	.	O
19	650	O
20	for	O
21	the	O
22	pulp	O
23	,	O
24	0	O
25	.	O
26	674	O
27	for	O
28	the	O
29	tongue	O
30	,	O
31	0	O
32	.	O
33	828	O
34	for	O
35	the	O
36	submandibular	O
37	gland	O
38	and	O
39	0	O
40	.	O
41	881	O
42	for	O
43	the	O
44	gingiva	O
45	of	O
46	the	O
47	dog	O
48	.	O
49	lambda	O
50	cp	O
51	increased	O
52	and	O
53	lambda	O
54	tp	O
55	decreased	O
56	as	O
57	the	O
58	temperature	O
59	was	O
60	reduced	O
61	from	O
62	37	O
63	to	O
64	4	O
65	degrees	O
66	C	O
67	.	O

1	Hybrid	O
2	-	O
3	selection	O
4	experiments	O
5	against	O
6	total	O
7	PB	O
8	-	O
9	inducible	O
10	RNA	O
11	were	O
12	performed	O
13	with	O
14	plasmid	O
15	DNA	O
16	derived	O
17	from	O
18	clones	O
19	enriched	O
20	in	O
21	PB	O
22	-	O
23	inducible	O
24	information	O
25	.	O

1	Importance	O
2	of	O
3	determining	O
4	the	O
5	blood	O
6	sulfhydryl	O
7	groups	O
8	in	O
9	fractures	O
10	of	O
11	the	O
12	long	O
13	tubular	O
14	bones	O
15	complicated	O
16	by	O
17	infection	O

1	3600	O
2	-	O
3	fold	O
4	to	O
5	apparent	O
6	homogeneity	O
7	with	O
8	a	O
9	41	O
10	%	O
11	yield	O
12	by	O
13	affinity	O
14	chromatography	O
15	utilizing	O
16	DNA	O
17	-	O
18	cellulose	O
19	;	O
20	the	O
21	purity	O
22	of	O
23	the	O
24	final	O
25	preparation	O
26	was	O
27	assessed	O
28	by	O
29	SDS	O
30	/	O
31	PAGE	O
32	,	O
33	lack	O
34	of	O
35	contamination	O
36	by	O
37	other	O
38	nucleases	O
39	and	O
40	production	O
41	of	O
42	a	O
43	monospecific	O
44	antibody	O
45	against	O
46	the	O
47	enzyme	O
48	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O

1	The	O
2	dynamic	O
3	properties	O
4	of	O
5	this	O
6	protein	O
7	fragment	O
8	were	O
9	measured	O
10	and	O
11	analyzed	O
12	using	O
13	both	O
14	isotropic	O
15	and	O
16	anisotropic	O
17	models	O
18	of	O
19	molecular	O
20	motion	O
21	.	O

1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O

1	Interplane	O
2	coupling	O
3	in	O
4	the	O
5	superconductor	O
6	Y2Ba4Cu7O15	O
7	as	O
8	revealed	O
9	by	O
10	NQR	O
11	spin	O
12	-	O
13	echo	O
14	double	O
15	resonance	O
16	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	O
12	a	O
13	critical	O
14	minimal	O
15	level	O
16	of	O
17	Ypt	B
18	protein	I
19	prenylation	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	vesicle	O
25	polarization	O
26	.	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	Clinical	O
2	research	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	post	O
12	-	O
13	transfusion	O
14	hepatitis	O

1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	B
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O

1	Altogether	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	Ypt51p	B
8	,	O
9	Ypt52p	B
10	,	O
11	and	O
12	Ypt53p	B
13	are	O
14	required	O
15	for	O
16	transport	O
17	in	O
18	the	O
19	endocytic	O
20	pathway	O
21	and	O
22	for	O
23	correct	O
24	sorting	O
25	of	O
26	vacuolar	B
27	hydrolases	I
28	suggesting	O
29	a	O
30	possible	O
31	intersection	O
32	of	O
33	the	O
34	endocytic	O
35	with	O
36	the	O
37	vacuolar	O
38	sorting	O
39	pathway	O
40	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	protein	O
7	kinase	O
8	MEKK1	B
9	can	O
10	induce	O
11	reporter	O
12	gene	O
13	expression	O
14	from	O
15	the	O
16	atrial	B
17	natriuretic	I
18	factor	I
19	(	O
20	ANF	B
21	)	O
22	promoter	O
23	,	O
24	a	O
25	genetic	O
26	marker	O
27	that	O
28	is	O
29	activated	O
30	during	O
31	in	O
32	vivo	O
33	hypertrophy	O
34	.	O

1	USA	O
2	80	O
3	,	O
4	3618	O
5	-	O
6	3622	O
7	)	O
8	The	O
9	two	O
10	proteins	O
11	show	O
12	36	O
13	%	O
14	identities	O
15	in	O
16	their	O
17	amino	O
18	acid	O
19	sequence	O
20	,	O
21	in	O
22	an	O
23	alignment	O
24	requiring	O
25	six	O
26	gaps	O
27	.	O

1	CONCLUSIONS	O
2	:	O
3	Two	O
4	consecutive	O
5	sets	O
6	of	O
7	transrectal	O
8	ultrasound	O
9	guided	O
10	sextant	O
11	biopsies	O
12	of	O
13	the	O
14	prostate	O
15	performed	O
16	in	O
17	a	O
18	single	O
19	office	O
20	visit	O
21	represent	O
22	a	O
23	cost	O
24	-	O
25	effective	O
26	biopsy	O
27	strategy	O
28	for	O
29	men	O
30	presenting	O
31	with	O
32	an	O
33	abnormal	O
34	digital	O
35	rectal	O
36	examination	O
37	and	O
38	/	O
39	or	O
40	elevated	O
41	serum	B
42	PSA	I
43	.	O

1	An	O
2	undilated	O
3	type	O
4	of	O
5	APBD	O
6	is	O
7	frequently	O
8	associated	O
9	with	O
10	AMT	O
11	and	O
12	we	O
13	believe	O
14	,	O
15	therefore	O
16	,	O
17	that	O
18	clinicians	O
19	should	O
20	be	O
21	aware	O
22	of	O
23	a	O
24	possible	O
25	coexistence	O
26	of	O
27	APBD	O
28	and	O
29	AMT	O
30	.	O

1	The	O
2	M	O
3	-	O
4	3	O
5	subtype	O
6	was	O
7	an	O
8	adverse	O
9	prognostic	O
10	factor	O
11	.	O

1	For	O
2	the	O
3	first	O
4	time	O
5	we	O
6	describe	O
7	deletion	O
8	and	O
9	point	O
10	mutations	O
11	within	O
12	the	O
13	plasma	B
14	membrane	I
15	family	I
16	of	I
17	guanylyl	I
18	cyclase	I
19	receptors	I
20	that	O
21	result	O
22	in	O
23	the	O
24	formation	O
25	of	O
26	effective	O
27	dominant	O
28	negative	O
29	proteins	O
30	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	neu	B
6	proto	I
7	-	I
8	oncogene	I
9	did	O
10	not	O
11	show	O
12	kinase	O
13	activity	O
14	or	O
15	transforming	O
16	properties	O
17	when	O
18	expressed	O
19	at	O
20	similar	O
21	levels	O
22	in	O
23	NIH	O
24	3T3	O
25	cells	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	complete	O
6	6	O
7	-	O
8	kilobase	O
9	cDNA	O
10	sequence	O
11	coding	O
12	for	O
13	a	O
14	chain	O
15	of	O
16	1775	O
17	amino	O
18	acids	O
19	,	O
20	as	O
21	well	O
22	as	O
23	the	O
24	genomic	O
25	structure	O
26	.	O

1	Conversely	O
2	,	O
3	the	O
4	inactive	O
5	dAK	B
6	subunit	I
7	is	O
8	progressively	O
9	activated	O
10	by	O
11	1	O
12	)	O
13	association	O
14	with	O
15	a	O
16	dGK	B
17	or	O
18	dCK	B
19	subunit	I
20	and	O
21	2	O
22	)	O
23	the	O
24	conformationally	O
25	driven	O
26	heterotropic	O
27	affect	O
28	of	O
29	dGuo	B
30	or	O
31	dCyd	B
32	bound	O
33	to	O
34	the	O
35	opposing	O
36	subunit	O
37	.	O

1	The	O
2	reduced	O
3	efficiency	O
4	in	O
5	the	O
6	glycosylase	B
7	activity	O
8	is	O
9	also	O
10	reflected	O
11	in	O
12	a	O
13	reduced	O
14	ability	O
15	of	O
16	S120K	B
17	MutY	I
18	to	O
19	prevent	O
20	DNA	O
21	mutations	O
22	in	O
23	vivo	O
24	.	O

1	Terminal	B
2	deoxynucleotidyl	I
3	transferase	I
4	-	O
5	mediated	O
6	nick	O
7	end	O
8	labeling	O
9	assays	O
10	revealed	O
11	that	O
12	hormonal	O
13	activation	O
14	of	O
15	the	O
16	PAX3	B
17	repressors	I
18	induced	O
19	extensive	O
20	apoptosis	O
21	that	O
22	correlated	O
23	with	O
24	down	O
25	-	O
26	regulation	O
27	of	O
28	BCL	B
29	-	I
30	X	I
31	(	I
32	L	I
33	)	I
34	expression	O
35	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	Hh	B
6	and	O
7	Patched	B
8	(	O
9	Ptc	B
10	)	O
11	act	O
12	through	O
13	those	O
14	Ci	B
15	binding	O
16	sites	O
17	to	O
18	modulate	O
19	the	O
20	level	O
21	of	O
22	Ci	B
23	-	O
24	dependent	O
25	transcriptional	O
26	activation	O
27	in	O
28	S2	O
29	cells	O
30	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	corresponding	O
7	cDNAs	O
8	indicates	O
9	that	O
10	,	O
11	via	O
12	alternative	O
13	splicing	O
14	,	O
15	the	O
16	rearranged	O
17	gene	O
18	codes	O
19	for	O
20	two	O
21	proteins	O
22	of	O
23	84	O
24	and	O
25	85	O
26	kD	O
27	(	O
28	p84	B
29	/	I
30	85	I
31	)	O
32	which	O
33	retain	O
34	the	O
35	DNA	O
36	-	O
37	binding	O
38	rel	B
39	domain	I
40	and	O
41	the	O
42	first	O
43	five	O
44	ankyrin	B
45	repeats	O
46	,	O
47	but	O
48	have	O
49	lost	O
50	their	O
51	carboxy	O
52	-	O
53	terminus	O
54	including	O
55	the	O
56	seventh	O
57	ankyrin	B
58	repeat	O
59	.	O

1	Purified	B
2	P7	I
3	could	O
4	be	O
5	assembled	O
6	onto	O
7	particles	O
8	lacking	O
9	P7	B
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	B
15	(	O
16	RNA	B
17	polymerase	I
18	)	O
19	and	O
20	P7	B
21	.	O

1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	O
21	time	O
22	of	O
23	the	O
24	second	O
25	operation	O
26	.	O

1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	O
9	VCAM	B
10	-	I
11	1	I
12	promoter	I
13	performed	O
14	with	O
15	chloramphenicol	B
16	acetyltransferase	I
17	constructs	I
18	revealed	O
19	that	O
20	Tax	B
21	was	O
22	trans	O
23	activating	O
24	the	O
25	VCAM	B
26	-	I
27	1	I
28	promoter	I
29	via	O
30	two	O
31	NF	B
32	-	I
33	kappaB	I
34	sites	I
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	O
45	VCAM	B
46	-	I
47	1	I
48	gene	I
49	promoter	I
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	B
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O

